Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Elias Jabbour(McGill University Health Centre), Jörge E. Cortes(Augusta University Health), Nitin Jain(Parul University), Marina Konopleva(Albert Einstein College of Medicine), Jeffrey L. Jorgensen(The University of Texas MD Anderson Cancer Center), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Marygrace Ward(The University of Texas MD Anderson Cancer Center), Rebecca Garris(The University of Texas MD Anderson Cancer Center), Corabelle Encarnacion(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Binru Huang(The University of Texas MD Anderson Cancer Center), Joie Alvarez(The University of Texas MD Anderson Cancer Center), Nicole Tippett(The University of Texas MD Anderson Cancer Center), Christopher Loiselle(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Joseph D. Khoury(University of Nebraska Medical Center), William G. Wierda(University of Maryland, Baltimore), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center)
Cited by 39
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k